N@N

Curis to Release Fourth Quarter and Year-end 2008 Financial Results and Hold Conference Call on February 10, 2009

_{//health-fitness.news-articles.net/content/2009/ .. nd-hold-conference-call-on-february-10-2009.html}
^{Published in Health and Fitness on Tuesday, February 3rd 2009 at 7:53 GMT, Last Modified on 2009-02-03 07:54:01 by Market Wire}  

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its fourth quarter financial results on Tuesday, February 10, 2009 before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss: (i) its Hedgehog pathway inhibitor program under collaboration with Genentech, (ii) CUDC-101, CUDC-305 and other proprietary targeted cancer programs, (iii) its financial results as of and for the fourth quarter and fiscal year ended December 31, 2008, and (iv) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.

To access the live conference call, please call (800) 510-9836 from the United States or Canada or (617) 614-3670 from other locations, shortly before 9:00 A.M. EST. The conference ID number is 40400342. The conference call can also be accessed on the Curis website at [ www.curis.com ] in the Investors section. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Tuesday, February 24, 2009. To access the replay, please call (888) 286-8010 from the United States or Canada or (617) 801-6888 from other locations and reference the conference ID number 79470633.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines for cancer. In expanding its drug development efforts in the field of cancer through its targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at [ www.curis.com ].